Total Payments
$2.8M
2024 Payments
$556,395
Companies
52
Transactions
3,690
Payment Breakdown by Category
Other$2.0M (72.4%)
Travel$325,412 (11.8%)
Consulting$243,052 (8.8%)
Food & Beverage$103,508 (3.7%)
Research$90,548 (3.3%)
Education$384.19 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 591 | 68.5% |
| Travel and Lodging | $325,412 | 852 | 11.8% |
| Consulting Fee | $243,052 | 87 | 8.8% |
| Food and Beverage | $103,508 | 2,086 | 3.7% |
| Unspecified | $90,548 | 27 | 3.3% |
| Honoraria | $74,229 | 26 | 2.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $25,859 | 9 | 0.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,950 | 5 | 0.4% |
| Education | $384.19 | 7 | 0.0% |
Payments by Type
General
$2.7M
3,663 transactions
Research
$90,548
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $476,577 | 501 | $0 (2024) |
| PFIZER INC. | $443,259 | 542 | $0 (2024) |
| GENZYME CORPORATION | $385,773 | 312 | $0 (2024) |
| Incyte Corporation | $252,197 | 188 | $0 (2024) |
| ABBVIE INC. | $225,259 | 250 | $0 (2024) |
| Lilly USA, LLC | $135,347 | 206 | $0 (2024) |
| Arcutis Biotherapeutics, Inc. | $126,744 | 125 | $0 (2024) |
| Galderma Laboratories, L.P. | $116,001 | 227 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $78,211 | 117 | $0 (2024) |
| Verrica Pharmaceuticals Inc. | $71,359 | 59 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $556,395 | 591 | Regeneron Healthcare Solutions, Inc. ($105,150) |
| 2023 | $611,824 | 650 | GENZYME CORPORATION ($110,750) |
| 2022 | $592,405 | 584 | Regeneron Healthcare Solutions, Inc. ($119,212) |
| 2021 | $234,312 | 369 | GENZYME CORPORATION ($63,666) |
| 2020 | $125,462 | 266 | Regeneron Healthcare Solutions, Inc. ($24,273) |
| 2019 | $323,123 | 520 | PFIZER INC. ($128,699) |
| 2018 | $167,708 | 362 | PFIZER INC. ($102,587) |
| 2017 | $155,640 | 348 | PFIZER INC. ($63,960) |
All Payment Transactions
3,690 individual payment records from CMS Open Payments — Page 1 of 148
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $147.15 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,697.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | Cabtreo (Drug), JUBLIA | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Food and Beverage | In-kind items and services | $5.77 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,840.00 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Travel and Lodging | In-kind items and services | $850.96 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $98.25 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $4.80 | General |
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $179.17 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $163.36 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $5.86 | General |
| Category: DERMATOLOGY | ||||||
| 12/12/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $5.22 | General |
| Category: DERMATOLOGY | ||||||
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $81.28 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $5.94 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | LEO Pharma Inc. | ADBRY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,263.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/06/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $764.78 | General |
| 12/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $303.35 | General |
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.63 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $741.60 | General |
| 12/03/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $415.02 | General |
| 12/03/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $180.32 | General |
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $28,896 | 4 |
| Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES) | Almirall LLC | $18,487 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $13,139 | 5 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly Export S.A. Puerto Rico Branch | $7,083 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $6,185 | 6 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $4,850 | 1 |
| A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $4,379 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH COSENTYX RESEARCH | Novartis Pharmaceuticals Corporation | $4,375 | 1 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $2,909 | 4 |
| A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $139.73 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
About Pearl Kwong, MD PHD
Pearl Kwong, MD PHD is a Dermatology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043309909.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Pearl Kwong, MD PHD has received a total of $2.8M in payments from pharmaceutical and medical device companies, with $556,395 received in 2024. These payments were reported across 3,690 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.9M).
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Pediatric Dermatology
- Location Jacksonville, FL
- Active Since 10/11/2006
- Last Updated 02/22/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1043309909
Products in Payments
- DUPIXENT (Biological) $829,249
- EUCRISA (Drug) $311,661
- OPZELURA (Drug) $249,035
- RINVOQ (Biological) $218,554
- TALTZ (Drug) $122,554
- CIBINQO (Drug) $93,082
- Winlevi (Drug) $76,865
- YCANTH (Drug) $71,359
- Zoryve (Drug) $56,802
- Seysara (Drug) $54,017
- EPIDUO FORTE (Drug) $51,370
- AKLIEF (Drug) $44,515
- ARAZLO (Drug) $36,411
- LITFULO (Drug) $29,971
- QBREXZA (Drug) $27,291
- TAPINAROF (Drug) $25,504
- WYNZORA (Drug) $22,957
- AMZEEQ (Drug) $21,361
- COSENTYX (Biological) $15,946
- AMELUZ (Drug) $14,079
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Jacksonville
Michael Bernhardt, Md, MD
Dermatology — Payments: $702,961
Dermatology $702,961
Kristen Stewart, M.d, M.D
Dermatology — Payments: $107,300
Dermatology $107,300
Jason Sluzevich, Md, MD
Dermatology — Payments: $61,523
Dermatology $61,523
Dr. Douglas Robins, Md, MD
Dermatology — Payments: $24,873
Dermatology $24,873
Jean Mcclintock, Md, MD
Dermatology — Payments: $14,036
Dermatology $14,036
John Morello, M.d, M.D
Dermatology — Payments: $12,575
Dermatology $12,575